6种预后特征在ER阳性乳腺癌中的性能比较:一项随机临床试验的二次分析
该研究为ATAC随机试验的预计划二次分析,纳入774例绝经后ER阳性ERBB2阴性早期乳腺癌患者,在临床治疗评分基础上比较6种多基因预后特征对远处复发的预后价值。结果显示,在淋巴结阴性患者中,ROR、BCI和EPclin提供显著更多的预后信息;在1-3枚阳性淋巴结患者中,所有检测的独立信息有限。
要点
- 淋巴结阴性患者中ROR、BCI和EPclin对总体及晚期远处复发预后价值显著优于其他特征。
- 1-3枚阳性淋巴结患者中所有6种分子检测的独立预后信息有限。
- 上述数据可辅助医生和患者在选择化疗和/或延长内分泌治疗时挑选合适检测。
核心结论
- 对于淋巴结阴性患者,ROR、BCI和EPclin对总体及晚期远处复发的预后价值显著更高。
- 对于1-3枚阳性淋巴结患者,任何检测提供的独立信息均有限。
研究设计与样本
- 研究为回顾性生物标志物分析,纳入774例绝经后ER阳性ERBB2阴性乳腺癌女性,其中591例淋巴结阴性。
- 该分析为ATAC随机临床试验的预计划二次研究,比较5年阿那曲唑 vs 他莫昔芬治疗并含10年随访数据。
主要发现
- ROR的HR为2.56(95%CI 1.96-3.35),BCI的HR为2.46(95%CI 1.88-3.23),EPclin的HR为2.14(95%CI 1.71-2.68)。
- 上述三者提供的信息显著多于临床治疗评分(HR 1.99,95%CI 1.58-2.50)、复发评分(HR 1.69,95%CI 1.40-2.03)和4标志物免疫组化评分(HR 1.95,95%CI 1.55-2.45)。
- 在183例1-3枚阳性淋巴结患者中,BCI(ΔLR χ2=9.2)和EPclin(ΔLR χ2=7.4)提供比其他特征更多的额外预后信息。
关键数值与推荐
- 预后价值通过似然比统计量(LR)结合χ2检验和C指数评估。
- 主要目标为比较各特征在临床治疗评分(淋巴结状态、肿瘤大小、分级、年龄和内分泌治疗)基础上对0-10年及5-10年远处复发的预后价值。
临床怎么用
- 对于淋巴结阴性ER阳性早期乳腺癌患者,可优先考虑ROR、BCI或EPclin以辅助化疗和/或延长内分泌治疗决策。
- 对于1-3枚阳性淋巴结患者,现有分子检测的独立预后信息有限,需谨慎解读。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Multiple molecular signatures are available for managing estrogen receptor (ER)-positive breast cancer but with little direct comparative information to guide the patient's choice. OBJECTIVE: To conduct a within-patient comparison of the prognostic value of 6 multigene signatures in women with early ER-positive breast cancer who received endocrine therapy for 5 years. DESIGN, SETTING, AND PARTICIPANTS: This retrospective biomarker analysis included 774 postmenopausal women with ER-positive ERBB2 (formerly HER2)-negative breast cancer. This analysis was performed as a preplanned secondary study of data from the Anastrozole or Tamoxifen Alone or Combined randomized clinical trial comparing 5-year treatment with anastrozole vs tamoxifen with 10-year follow-up data. The signatures included the Oncotype Dx recurrence score, PAM50-based Prosigna risk of recurrence (ROR), Breast Cancer Index (BCI), EndoPredict (EPclin), Clinical Treatment Score, and 4-marker immunohistochemical score. Data were collected from January 2009, through April 2015. MAIN OUTCOMES AND MEASURES: The primary objective was to compare the prognostic value of these signatures in addition to the Clinical Treatment Score (nodal status, tumor size, grade, age, and endocrine treatment) for distant recurrence for 0 to 10 years and 5 to 10 years after diagnosis. Likelihood ratio (LR) statistics were used with the χ2 test and C indexes to assess the prognostic value of each signature. RESULTS: In this study of 774 postmenopausal women with ER-positive, ERBB2-negative disease (mean [SD] age, 64.1 [8.1] years), 591 (mean [SD] age, 63.4 [7.9] years) had node-negative disease. The signatures providing the most prognostic information were the ROR (hazard ratio [HR], 2.56; 95% CI, 1.96-3.35), followed by the BCI (HR, 2.46; 95% CI, 1.88-3.23) and EPclin (HR, 2.14; 95% CI, 1.71-2.68). Each provided significantly more information than the Clinical Treatment Score (HR, 1.99; 95% CI, 1.58-2.50), the recurrence score (HR, 1.69; 95% CI, 1.40-2.03), and the 4-marker immunohistochemical score (HR, 1.95; 95% CI, 1.55-2.45). Substantially less information was provided by all 6 molecular tests for the 183 patients with 1 to 3 positive nodes, but the BCI (ΔLR χ2 = 9.2) and EPclin (ΔLR χ2 = 7.4) provided more additional prognostic information than the other signatures. CONCLUSIONS AND RELEVANCE: For women with node-negative disease, the ROR, BCI, and EPclin were significantly more prognostic for overall and late distant recurrence. For women with 1 to 3 positive nodes, limited independent information was available from any test. These data might help oncologists and patients to choose the most appropriate test when considering chemotherapy use and/or extended endocrine therapy. TRIAL REGISTRATION: isrctn.com Identifier: ISRCTN18233230.
引用
- Sestak I, Buus R, Cuzick J, et al. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018. PMID: 29450494. doi:10.1001/jamaoncol.2017.5524
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。